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This study aims to confirm the usefulness of patient-specific quality assurance (PSQA)
using three-dimensional (3D)-printed phantoms in ensuring the stability of IORT and the
precision of the treatment administered. In this study, five patient-specific chest phantoms
were fabricated using a 3D printer such that they were dosimetrically equivalent to the
chests of actual patients in terms of organ density and shape around the given target,
where a spherical applicator was inserted for breast IORT treatment via the
INTRABEAM™ system. Models of lungs and soft tissue were fabricated by applying
infill ratios corresponding to the mean Hounsfield unit (HU) values calculated from CT
scans of the patients. The two models were then assembled into one. A 3D-printed water-
equivalent phantom was also fabricated to verify the vendor-provided depth dose curve.
Pieces of an EBT3 film were inserted into the 3D-printed customized phantoms to
measure the doses. A 10 Gy prescription dose based on the surface of the spherical
applicator was delivered and measured through EBT3 films parallel and perpendicular to
the axis of the beam. The shapes of the phantoms, CT values, and absorbed doses were
compared between the expected and printed ones. The morphological agreement among
the five patient-specific 3D chest phantoms was assessed. The mean differences in terms
of HU between the patients and the phantoms was 2.2 HU for soft tissue and −26.2 HU
for the lungs. The dose irradiated on the surface of the spherical applicator yielded a
percent error of −2.16% ± 3.91% between the measured and prescribed doses. In a
depth dose comparison using a 3D-printed water phantom, the uncertainty in the
measurements based on the EBT3 film decreased as the depth increased beyond 5
mm, and a good agreement in terms of the absolute dose was noted between the EBT3
film and the vendor data. These results demonstrate the applicability of the 3D-printed
chest phantom for PSQA in breast IORT. This enhanced precision offers new
opportunities for advancements in IORT.
Keywords: intraoperative radiation therapy (IORT), patient-specific quality assurance, 3D printing, INTRABEAM™,
breast cancerMarch 2021 | Volume 11 | Article 6299271
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Intraoperative radiation therapy (IORT) is a treatment modality
that entails accelerated partial breast irradiation for early-stage
breast cancer patients (1, 2). IORT generally refers to the direct
delivery of a single-fraction dose of highly localized radiation to
the periphery of the lumpectomy bed during surgery (3). Its
major advantage is that it offers the direct visualization of the
tumor bed without incurring the risk of a marginal miss. This
helps minimize damage to the healthy tissue by reducing the
volume and dose of radiation to the normal surrounding tissue
(4). Furthermore, compared with conventional whole-breast
irradiation (WBI) over 5 to 5.5 weeks followed by tumor-bed
boost or hypofractionated WBI over 3 weeks with a boost, IORT
is completed in one day, and intraoperative irradiation allows for
the immediate treatment of the surgical bed in 30 min to avoid a
delay between surgery and external beam radiotherapy. This is
convenient for the patient and helps reduce cost. Treating a smaller
volume of normal tissue instead of performing WBI enables the
reduction of potential lung and cardiac toxicities arising from
radiation treatment and enhances tumor control (5–7).
IORT requires specialized radiotherapy equipment. In this
regard, INTRABEAM™ (Carl Zeiss Surgical GmbH, Oberkochen
Germany) uses a low-energy (50 kV) X-ray generator to provide
partial-breast irradiation (8). This system uses spherical applicators
to deliver a uniform dose on the inner surface of the breast
lumpectomy cavity and irradiates high-dose (10–20 Gy) beams at
once. Therefore, it is essential to ensure safe and accurate delivery
through a patient-specific quality assurance (PSQA) process that
verifies that the treatment device is physically capable of delivering
the expected dose distribution prior to patient treatment. Because
the radiation dose cannot be measured directly in the patient, it is
common to create phantoms that mimic human radiation
characteristics. Patient-specific dose measurements are often
performed using radiation therapy phantoms combined with
various dosimeters. These phantoms are made of homogeneous
materials that simulate representative organs. However,
commercially available phantoms for IORT are not supported for
clinical use. Moreover, because most IORT clinics do not have a
treatment planning system (TPS), a thorough understanding of the
dose distribution of IORT is essential for safe, effective, and efficient
treatment delivery. Special attention needs to be paid to all aspects of
the treatment for each patient. However, it is difficult to perform
accurate predictions regarding IORT because the volume of the
tumors removed may vary depending on the surgery outcome.
Thus, pretreatment planning and PSQA are limited (9, 10).
There have been attempts to manufacture customized objects
incorporating 3D printing technology into various applications of
radiation therapy (11–17). In this manner, to overcome the
limitations of IORT’s PSQA, we ensure the stability of IORT by
creating a PSQA phantom via 3D printing. This study investigates
the feasibility of verifying IORT dosimetry using a 3D-printed
water-equivalent phantom as well as patient-specific 3D chest
phantoms fabricated by simulating the actual structure of the body
of the patient around the target. We explore the effectiveness of the
3D-printed phantoms fabricated by considering the infill ratio
corresponding to the average HU value assigned to the patient’sFrontiers in Oncology | www.frontiersin.org 2CT. We also examine the qualification and quantification of
the depth dose and the dose administered on the surface of
the applicator to ensure that the delivered dose matches the
expected dose.MATERIALS AND METHODS
INTRABEAM™ System
The INTRABEAM™ system consists of a miniaturized
accelerator (XRS) that accelerates electrons through a 10-cm
drift tube, with a maximum voltage of 50 kV, onto a gold target
where low-energy photons are produced and then emitted
isotropically. An internal radiation monitor is used to detect
the X-ray photons emitted in the direction of the cathode and
record the dose output in real time. The miniaturized accelerator
is inserted into the arm of the INTRABEAM carrier, which can
be moved smoothly to any position in the operating room owing
to the integral casters located at its base. Weight compensation
and six axes provide sufficient freedom to place the miniaturized
accelerator in any position in 3D space for access to the targeted
area. Electromagnetic brakes hold the miniaturized accelerator in
the exact set position during treatment. The operator can know
the dose being delivered at any time throughout the treatment
through the online dose monitoring data displayed on the
treatment screen of the control terminal on the INTRABEAM
cart. Spherical applicators are used for the intracavitary or
intraoperative delivery of radiation to the tumor bed, e.g.,
during breast-conserving surgery. The applicator fills the cavity
created by the excision of the tumor. The tissue on the tumor bed
adheres to the applicator via surface tension. The probe tip is
centered within the applicator and, therefore, at the tumor cavity.
The INTRABEAM spherical applicators, which are reusable and
sterilizable, are available in 5 mm increments, with diameters
ranging from 15 mm to 50 mm. In this study, applicators with a
diameter of 35 mm were used.
Absolute Dosimetry Using Zeiss
Water Phantom
Zeiss supplies a special water phantom consisting of a 3D
translational stage for precise source positioning and a PTW
34013 soft X-ray ionization chamber (18). To calculate the
dosage rate in water for the XRS using this phantom, Eq. 1 is
suggested in the user manual (19):
DRZeissw = MrawPTPNkKQKKQ!DW , (1)
where Nk is the ion chamber calibration factor (Gy/nC), Mraw is
the ionization charge (C) collected in 60 s for a chamber located
at depth z in water, and PTP is the correction factor for room
temperature (T) and pressure (P) at the time of dose
measurement. The beam quality correction factor, KQ, was set
to unity (KQ = 1) based on the fact that the T30 spectrum used as
a reference X-ray beam, with Eeff =16.4 keV and HVL=0.43 mm
AI, best matched the INTRABEAM spectrum (18). KKQ!DW was
the chamber conversion factor that converted air kerma
measurements into doses in water for the chamber in the T30March 2021 | Volume 11 | Article 629927
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calibration depth dose curve, where the measured DRZeissw was
plotted as a function of depth z.
Fabrication of 3D-Printed
Customized Phantom
Figure 1 illustrates the schematic design of the customized chest
phantom fabricated by the 3D printer. CT image data for each
patient, in the digital imaging and communications in medicine
file format, were used to create a virtual 3D-printed chest phantom.
A CT slice was collected every 3 mm and reconstructed as a 1-mm-
spaced slice. Modifications to the CT images were performed using
the MIM Maestro software (version 6.1, MIM Software Inc., USA).
The growth in the seed region, followed by a manually adjusted 2D
brush, was used to select the region of interest (ROI) that covered
one side of the lung close to the tumor and the ROI that
corresponded to the soft tissue including the breast. The mean
HU values of voxels in each ROI were calculated.
3D Slicer was used to define the initial virtual object to form
the 3D chest phantom based on the patient’s CT data. The virtual
object with surface information in terms of triangular meshes
was stored in the stereolithography (STL) file format, and it
could be read by the 3D printer software. Using Blender, the
converted raw 3D object was refined by disregarding any
defective meshes using the built-in “shrink-wrap” function. In
addition, we prepared a spherical applicator space by considering
the size of the tumor to be removed from the site where the IORT
applicator would be inserted. It was also formed in four parts so
that pieces of the EBT3 film could be placed horizontally and
vertically between parts.Frontiers in Oncology | www.frontiersin.org 3Based on this new surface, the 3D-printable customized chest
phantom was fabricated using a fused deposition-modeling
(FDM) 3D printer (DP200; 3D WOX, Sindoh, South Korea)
that employed a polylactic acid (PLA) filament with a physical
density (r) of 1.25 g/cm3. The printing parameters comprised a
speed of 20 mm/s and layer thickness of 0.2 mm. The other
parameters were determined after the calibration. The infill
ratios of FDM were determined by the calculated mean HU
values of the soft tissue and the lung using the correlation curve
between the HU and the infill ratio.
To create the correlation curve, 10 rectangular samples
(width × length × height = 40 mm × 40 mm × 20 mm) were
created by varying infill ratios from 10% to 100%. The infill ratios
ranged from 0% to 100%, which is the ratio of the volume of a
printed thermoplastic to that of air. The samples were printed in
a grid pattern using PLA material and the FDM method, which
were fabricated by varying the infill ratio by 10%. In total 10
samples, with infill values ranging from 10% to 100%, were
scanned to a thickness of 1 mm using a Siemens SOMATOM
Definition AS CT Scanner (Siemens Healthcare, Erlangen,
Germany), at a voltage of 120 kV and current of 10 mA. All HU
measurements, such as the maximum, minimum, and mean, were
obtained using an ROI of 30mm× 34mm× 15mmon the scanned
CT image. Figure 2 shows the linear relationship between the infill
value (%) and HU as the infill ratios of the 3D printer were
increased from 10% to 100% in increments of 10 percentage
points. For the linear trend line, we derived an equation of y =
11.438x – 1,005.9, where the R2 value was 0.997. As a result, the HU
was obtained by varying the infill ratios from 10% to 100%, thereby
changing the average HU from −882 to 148.FIGURE 1 | Schematics of creating 3D-printed chest phantom.March 2021 | Volume 11 | Article 629927
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fabricated by applying infill ratios corresponding to the
calculated mean HU values. We then assembled the two
models into one. The 3D-printed water-equivalent phantom
was also fabricated to reflect an infill ratio corresponding to 0
HU to verify the vendor-provided depth dose curve. As shown in
Figure 3, the water-equivalent phantom was sectioned into
upper and lower parts, including a space for the spherical
applicator. A piece of EBT3 film was placed between separate
parts perpendicular to the spherical applicator.
Gafchromic EBT3 Film Calibration
A Gafchromic EBT3 film was used for dose measurement by
using patient-specific 3D chest phantoms. The EBT3 film
consisted of a 28-mm-thick active layer and 125-mm-thickFrontiers in Oncology | www.frontiersin.org 4protective layers covering the active layer. Scanning the film
before and after irradiation and measuring its optical density
allowed us to measure the dose delivered to the film. The optical
density of the exposed film was converted into a dose via the dose
calibration curve.
Dose calibration was performed using a parallel-plate
ionization chamber (PTW 23342, Germany) and the EBT3
fi lm on the same INTRABEAM™ system through a
conventional technique (20), with exposures ranging from 0 to
20 Gy. The ionization chamber was positioned on the surface of
the EasyCube® phantom (Sun Nuclear Corporation, FL, USA),
which consisted of water-equivalent slabs of different dimensions
and a customized housing holder. The dimensions of the
phantom were 16 cm × 16 cm × 8 cm, as shown in Figure 4.
The absolute dose outputs within the range of doses of interest
were measured to determine the durations of treatment in terms
of absorbed doses on the phantom surface in contact with the
spherical applicator (with a diameter of 35 mm). Each piece of
the EBT3 film placed on the surface of the phantom was exposed
to nine absorbed doses (0, 0.2, 0.5, 1, 2, 5, 10, 15, and 20 Gy) to cover
the full dynamic range of the film. All measurements of the film
were performed twice to verify the reproducibility of the results.
The exposed EBT3 films were digitized using the
commercially available Vidar Dosimetry Pro Advantage Red
digitizer. The results were analyzed using the RIT version 6.1
software package (RIT, Denver, CO, USA). Uniform ROIs
corresponding to the center of each film (10×10 mm2 subsets)
were chosen for 16-bit red channel calibration. A third-degree
polynomial function was used to fit the calibration curve of the
film, as shown in Figure 5.
To obtain precise and reproducible film dosimetry results, the
films were scanned over the same period (24 h irradiation-to-FIGURE 2 | Correlation curve between mean HU and infill ratio.A B
FIGURE 3 | 3D-printed water-equivalent phantom made of PLA material. (A) The upper and lower parts for the ease of the reproducible placement of a piece of
EBT3. (B) The film was along the vertical direction relative to the surface of applicator.March 2021 | Volume 11 | Article 629927
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orientation because process consistency is crucial to reducing
potential uncertainties.
Measurements and Data Analysis
The Institutional Review Board of the Gangnam Severance
Hospital, Korea (IRB No. 3-2017-0033), approved this
prospective study in accordance with ethical guidelines and the
Declaration of Helsinki.
All measurements were carried out in the 3D-printed water-
equivalent phantom as well as the patient-specific 3D chest
phantoms created based on five patients receiving IORT. In the
water-equivalent phantom, a piece of EBT3 film was exposed
parallel to the axis of the beam by placing it along the border of
the space for the spherical applicator and between the upper and
lower parts of the phantom. This made it possible to bring one
side of the film in direct contact with the applicator. The depth
dose measured using the film was compared with the depth dose
curve provided by the supplier.
For the patient-specific 3D chest phantoms, the piece of EBT3
film was placed on a horizontal plane perpendicular to the axis ofFrontiers in Oncology | www.frontiersin.org 5the radiation beam. The central region of the piece of film was in
direct contact with the surface of the spherical applicator, which
had a diameter of 35 mm. The other piece of the film was
inserted between separate parts of the phantom in a vertical
plane parallel to the axis of the radiation beam (Figure 6). The
treatment duration was calculated such that a 10 Gy dose was
delivered on the surface of the applicator.
All exposed films were processed to quantify the dose
distributions via the dose calibration curve using RIT. A 5 × 5
median filter was applied to each film, and random outliers were
excluded from the analysis. The point dose measured from the
film placed on the horizontal plane was determined via the
maximum value extracted from the dose histogram of each
irradiated film. Depth dose curves were acquired at depths
from 0 to 30 mm through the profile of a piece of film placed
on the vertical plane.RESULTS
Evaluations With a 3D-Printed
Water-Equivalent Phantom
For precise dosimetric examination, it is necessary to ensure that
the 3D-printed density matches the preset density of the infill
(14). A CT scan of the 3D-printed water-equivalent phantom
was performed to calculate the actual density by comparing it
with values in an image value-to-density table. The 3D-printed
water-equivalent phantom exhibited a mean of 7 ± 59 HU, in the
range from −190 HU to 195 HU. The actual average density was
1.003 g/cm3. Table 1 shows the differences in dose at each depth,
between data provided by the vendor and those obtained from
the EBT3 film parallel to the axis of the beam, obtained using the
3D-printed water-equivalent phantom. The average of three
measurements was reported as the representative estimate, and
its estimated uncertainty was based on the absolute value of the
difference between each measurement and the average value. The
average difference between the vendor and EBT3 film data wasFIGURE 4 | Slab water phantom setup with a parallel plate ionization chamber (left) and an EBT3 film (right) for film calibration.FIGURE 5 | Dose calibration curve for the EBT3 film.March 2021 | Volume 11 | Article 629927
Choi et al. Patient-Specific Quality Assurance for IORT18.3 ± 24.9 cGy (1.8% ± 2.5%), with a difference of up to 64.3 cGy
(6.4%) found at a depth of 5 mm. The mean uncertainty in the
EBT3 measurement was 16.8 cGy (a maximum of 83.9 cGy at a
depth of 0 mm). The measured dose was underestimated at a
depth of 0 mm, which corresponded to the border of the piece of
film; specifically, this underestimation occurred because of
increased uncertainty due to the damage caused by cutting the
EBT3 film into pieces. As the depth increased beyond 5 mm, the
uncertainty in the measurements performed using the EBT3 film
decreased, and a good agreement in terms of absolute dose was
obtained between the EBT3 film and the vendor data.
Evaluations With 3D-Printed
Patient-Specific Chest Phantoms
Chest phantoms of five patients were fabricated for PSQA
measurements. IORT patients were randomly selected and the
applicator was used for PSQA measurements. Table 2 shows
the location of the dose measurement for each patient and the
distance between the tumor and the lung. The mean and
standard deviation of the HU values of the voxels inside each
ROI (soft tissue and lung) were calculated. Based on an infill ratio
corresponding to the mean HU value, the customized chestFrontiers in Oncology | www.frontiersin.org 6phantoms were fabricated using the 3D printer, as shown in
Figure 7. The 3D-printed soft tissue and lung were sectioned in
four and two parts, respectively, to facilitate the reproducible
positioning of the spherical applicator and pieces of film. Table 3
shows the HU values of the soft tissue and the lung parts for the
five patient-specific 3D chest phantoms. On average, differences
in the HU between the patient and the phantom were 2.2 HU for
soft tissue and −26.2 HU for the lung. This was in close
agreement with the expected HU in terms of the calculated
doses. Because eachpartwas printed sequentially, it took19~50h to
fabricate a single phantom depending on the amount of filamentFIGURE 6 | Dose measurement using EBT3 film and patient-specific chest phantom. The spherical application surface dose was measured by placing the EBT3
film on a horizontal plane perpendicular to the axis of the radiation beam (Left), and EBT3 film was placed on a vertical plane parallel to the axis of the radiation beam
to measure the depth dose away from the applicator surface (Right).TABLE 1 | Comparison between the measured dose from the EBT3 film parallel to the beam axis and vendor-provided depth dose at different depths using the 3D-
printed water-equivalent phantom.






1st trial 2nd trial 3rd trial Mean ± stdev.
0 937.2 939.9 1,083.8 987.0 ± 83.9 1,000 −13.0 −1.3
5 493.8 514.9 528.3 512.3 ± 17.4 448 64.3 6.4
10 271.3 281.9 280.9 278.0 ± 5.8 242 36.0 3.6
15 158.9 154.1 161.3 158.1 ± 3.6 145 13.1 1.3
20 100.8 95.6 98.4 98.2 ± 2.6 93 5.2 0.5
25 74.9 70.8 73.1 72.9 ± 2.1 63 9.9 1.0
30 58.5 54.5 56.9 56.6 ± 2.0 44 12.6 1.3March 2021 | Volume 11 | ArticPercent error (%) = dose difference/prescription dose × 100%.TABLE 2 | Information on the five patients who received breast IORT.




HU of patient CT (mean ± st. dev.)
Soft tissue Lung
Patient 1 Left upper ≤1 cm −60 ± 53 HU −582 ± 182 HU
Patient 2 Left upper ≤1 cm −38 ± 52 HU −800 ± 158 HU
Patient 3 Right upper >1 cm −44 ± 55 HU −725 ± 140 HU
Patient 4 Left lower >1 cm −61 ± 53 HU −803 ± 153 HU
Patient 5 Right lower ≤1 cm −37 ± 59 HU −713 ± 162 HUle 629927
Choi et al. Patient-Specific Quality Assurance for IORTused. The weight of the filament used ranged from 329 g to 975 g.
The 3D printing process required only approximately 30 min of
labor to fill, clean, assemble, and verify the printed phantom. The
infill ratio of printing ranged from 83% to 85% for soft tissue and
18% to 37% for the lung. The Dice similarity coefficient (DSC) wasFrontiers in Oncology | www.frontiersin.org 7considered to quantify the similarity between the corresponding
structures. The DSC ranges from 0 (no overlap) to 1 (perfect
overlap). A large DSC value indicates good overlap between the
3D-printed phantom and the patient. As shown in Figure 8, CT
images of the patients and those of their corresponding phantomsA
B
FIGURE 7 | 3D-printed patient-specific chest phantom: (A) A set of phantoms representing the soft tissue and lung, and (B) cross-sections of the soft tissue and
lung of the five patients. The left-to-right columns are from PSQA1 to PSQA5.TABLE 3 | Printing information, HU, HU difference, and Dice similarity coefficient (DSC) for the five patient-specific 3D chest phantoms fabricated by using a 3D printer.
PSQA 1 PSQA 2 PSQA 3 PSQA 4 PSQA 5
Printing time
(soft tissue + lung)
2,994 min. 1,147 min. 3,049 min. 1,441 min. 1,731 min.
Amount of filament 615 g 329 g 975 g 404 g 452 g
HU of phantom CT
(mean ± st. dev.)
Soft tissue −48 ± 29 HU −42 ± 29 HU −49 ± 92 HU −56 ± 74 HU −56 ± 83 HU
Lung −580 ± 96 HU −793 ± 154 HU −680 ± 124 HU −762 ± 184 HU −705 ± 172 HU
HU Difference between
patient CT and phantom CT
Soft tissue −12 4 5 −5 19
Lung −2 −7 −45 −41 −8
DSC between patient CT
and phantom CT
Soft tissue 0.97 0.97 0.97 0.98 0.97
Lung 0.97 0.98 0.97 0.96 0.97March 2021 | Volume 11 | Article 629927
Choi et al. Patient-Specific Quality Assurance for IORTwere visually matched and then fused to calculate the DSC in the
soft tissue and the lung, respectively. On average, the DSC between
the patient and the phantomwas 0.97 for the soft tissue and 0.97 for
the lung.
Table 4 shows the differences between the 1,000 cGy dose
administered on the surface of the 35-mm spherical applicator
and the dose measured from the pieces of film perpendicular to
the axis of the beam. The film measurements ranged from 930.2
cGy to 1,025.6 cGy for the five patient-specific chest phantoms.
An evaluation of these measurements versus the prescribed dose
indicates that the mean dose difference was −21.6 ± 39.1 cGy,
and the mean percentage error was −2.16% ± 3.91%.
Figure 9 shows the depth dose measurements of the five
PSQA phantoms using pieces of film parallel to the axis of the
beam. The measured dose at shallow depths along the border of
the film had been underestimated. A depth of 2 to 3 mm was
found to be adequate to initiate the depth dose curve. This
implies that the first few millimeters along the border of the film
could not be used when performing parallel film measurements
because the EBT3 film was cut into pieces. This finding is
consistent with those of previous studies (21, 22), which have
reported damage to the film pieces. Unlike megavoltage-scale X-
rays, kilovoltage-scale depth dose curves produced by
INTRABEAM™ led to a steep fall-off in the dosage with
depth. This is beneficial to the organs at risk in the
environment of the lesion and allows radiation oncologists to
prescribe higher doses to the lesion itself.DISCUSSION
Few studies have examined PSQA for IORT. This subject is of
particular concern in the context of single-session radiotherapy
techniques such as IORT where there is no opportunity to
compensate for possible errors in later treatment sessions. In
light of this, this study developed a simple and non-toxic PSQA
method for IORT using 3D printing. The results confirm the
feasibility of PSQA for IORT using a 3D printer and a
conventionally used PLA filament to fabricate a patient-specific
chest phantom. FDM printers are the most economical 3DFrontiers in Oncology | www.frontiersin.org 8printers, and they will be advantageous for future clinical
applications. In this study, only one FDM-type 3D printer was
used to fabricate the patient-specific chest phantoms. The
fabricated phantoms can be evaluated in terms of the lung
(−803 to −582 HU) and soft tissue (−61 to −37 HU), which
have a lower physical density than water, by changing the infill
ratio. Although differences in HU values between the patients
and the phantoms were observed (the DHU of soft tissue =FIGURE 8 | Image fusion between the patient’s CT and the 3D-printed phantom CT.TABLE 4 | Comparison between the measured dose from the EBT3 film placed
on the horizontal plane perpendicular to the beam axis and the prescription dose










PSQA 1 1,000 992.2 −7.8 −0.78
PSQA 2 1,000 930.2 −69.8 −6.98
PSQA 3 1,000 997.5 −2.5 −0.25
PSQA 4 1,000 946.5 −53.5 −5.35
PSQA 5 1,000 1025.6 25.6 2.56March 2021 | Volume 11 | ArFIGURE 9 | Depth doses measured from the EBT3 film parallel to the beam
axis using the five 3D chest phantoms on the INTRABEAM™ system using a
35 mm spherical applicator.ticle 629927
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environment, the dosimetric influences of these differences were
not significant, based on the fact that it is appropriate to set
tolerances of ±20 HU for soft tissue and ±50 HU for lungs when
restricting changes in dose in the treatment plan to within
±1% (23).
For dose measurements using the patient-specific chest
phantom assembled in the manner described above, the films
were exposed along two directions: perpendicular and parallel to
the axis of the beam. On the surface of the applicator, the
horizontal plane was better than the vertical plane because the
border of the piece of film could be damaged. In a depth dose
comparison using a 3D-printed water phantom, the average
difference between the measurements provided by the vendor
and those of the actual EBT3 film was the greatest at a depth of 5
mm, but a substantial difference in the dose gradient was
observed between 0 and 10 mm; this is because the dose
decreased by 75% from the surface of the applicator to a depth
of 10 mm. In this case, the main cause of uncertainty in the
measurement was the positioning of the detector. As has been
determined in previous studies (24, 25), both the ionization
chamber and the dosimetry of the film can be performed with an
accuracy of 5%–10%, when considering the largest error due to
the positioning of the dosimeter. Based on this fact, the steep
dose gradients produced by the INTRABEAM system yielded a
10% difference in dose for a 1 mm difference in distance. This
inherent variation, combined with the uncertainties involved in
practical measurements using different dosimeters, may preclude
even a 5% tolerance in the depth doses. Therefore, a 10% dose
difference may be acceptable at a steep dose gradient.
The morphology of patients was accurately reproduced to
fabricate customized phantoms. The designs produced here were
found to be robust and can be easily modified to add strength as
needed. If 3D-printed parts break, they can be accurately
reproduced with minimal additional labor. With more time, it
will be possible to produce 3D-printed phantoms with even
greater heterogeneity. It is evident that this has copious potential
benefits for the stage of clinical adaptation. Therefore, this 3D
printing technology can be employed to fabricate accurate shapes
that reflect the spherical applicator and patients’ anatomical
structure, which in turn makes it possible to simultaneously
review the absolute dose to the lesion and the surrounding
organs at risk. This improves patient safety through the PSQA
prior to IORT. The digital workflow ensures the accuracy and
reproducibility of the procedure.
This study on prototype phantoms for IORT-specific PSQA
involves a few practical considerations. First, our study focused
on structures with low densities, by excluding bone structures,
because the surface of the spherical applicator was attached to the
soft tissue between the ribs. To incorporate the bone structure by
using 3D printing, we can assemble the structure using an FDM
lung and soft tissue model to replicate the CT values of the bones
using color-jet printing materials with more than 1,000 HUs
(26). For further investigation, contrast agents with different
concentrations can be injected into voids inside the 3D-printed
part to obtain a higher range of up to +1,000 HU (27). Second,Frontiers in Oncology | www.frontiersin.org 9the experiment used only five cases, as printing individual
phantoms is time and resource intensive. On average, a single
phantom fabrication took 35 h. This 3D printing process might
not be practical for general PSQA. However, given the rapid pace
of development of 3D printing at present, these technologies are
expected to improve dramatically over the next few years to
provide better convenience, speed, and precision. Third,
standard printing procedures should be used to ensure
consistency. Special caution should be taken regarding the first
layer of each print, as distortion can be caused by the material
not completely sticking to the print bed.
Our study has some limitations. First, the PSQA phantom
fabrication described in this study may not adequately reproduce
all the uncertainties arising in clinical settings. In the breast IORT
procedure, a spherical applicator is placed inside the tumor cavity,
then the wall of the tumor cavity is pulled firmly to the applicator
surface using a purse-string suture. This process can lead to soft
tissue compression due to pre-fixation pressure as well as potential
air gaps near the applicator surface in some areas of the breast.
Additionally, contrary to our study assuming that the position of
the applicator in the intercostal space excludes bone-equivalent
heterogeneity in the phantom, in some cases during this fixation
process the position of the applicator may be on the ribs. In this
case, there may be a significant dose in the ribs. Second, skin and
subcutaneous tissue doses are a significant problem with breast
IORT. In our study, skin measurements were not taken into
account in the PSQA phantom because an optically stimulated
luminescence dosimeter was clinically used for in vivo dosimetry
to detect radiation doses delivered to the skin during breast IORT
(28). However, the most common late toxicity, with a maximum
appearance four years following treatment, is telangiectasia. The
development of telangiectasia is strongly correlated with the doses
applied to the subcutaneous vessels. Measuring the skin dose on
the PSQA phantom can help prevent the onset of severe
telangiectasia after several years. Therefore, PSQA phantom
development must incorporate this skin measurement prior to
patient treatment; this leads to a more secure treatment through
personalized pretreatment dosimetry investigations. Nevertheless,
owing to the absence of sufficient QA data regarding IORT, our
method for creating a simplified phantom composed of soft tissue
and lung models could be an important milestone in mimicking
personalized dosimetry.CONCLUSIONS
In this study, patient-specific 3D-printed chest phantoms were
successfully constructed to simulate the IORT-related dose
distributions to cancerous tumors, surgical tumor bed, and the
surrounding low-density organs such as lungs and soft tissue.
This allows not only for the prediction of the depth dose at
various distances from the spherical applicator, but also for the
verification of the dose by comparing the prescribed dose to the
expected dose. The proposed 3D printing methodology provides
a viable and inexpensive method for fabricating variable-densityMarch 2021 | Volume 11 | Article 629927
Choi et al. Patient-Specific Quality Assurance for IORTsolid phantoms for breast IORT-specific PSQA. This enhanced
precision offers new opportunities for advancing IORT.DATA AVAILABILITY STATEMENT
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